Back to Report Store Home

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

  • Published: May-2018
  • Report Code: GBIHC475MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Schizophrenia, US, Innovation Trends in Product Approvals, 1987–2014 6

Figure 2: Schizophrenia, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 8

Figure 3: Schizophrenia, Global Market by Molecular Target and Molecule Type, 2018 19

Figure 4: Schizophrenia, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 20

Figure 5: Schizophrenia, Global, Pipeline by Stage of Development and Molecule Type, 2018 21

Figure 6: Schizophrenia, Global, Pipeline by Molecular Target and Stage of Development, 2018 22

Figure 7: Schizophrenia, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2018 23

Figure 8: Schizophrenia, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2018 24

Figure 9: Schizophrenia, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2018 25

Figure 10: Schizophrenia, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018 26

Figure 11: Schizophrenia, Global, All Pipeline Programs, 2018 (part 1) 27

Figure 12: Schizophrenia, Global, All Pipeline Programs, 2018 (part 2) 28

Figure 13: Schizophrenia, Global, All Pipeline Programs, 2018 (part 3) 29

Figure 14: Schizophrenia, Global, All Pipeline Programs, 2018 (part 4) 30

Figure 15: Schizophrenia, Global, All Pipeline Programs, 2018 (part 5) 30

Figure 16: Schizophrenia, Global, First-in-Class Molecular Target Matrix Assessment, 2018 33

Figure 17: Schizophrenia, Global, Industry-Wide Licensing Deals by Stage of Development, 2006–2014 44

Figure 18: Schizophrenia, Global, Industry-Wide Deals by Stage of Development, 2006–2014 45

Figure 19: Schizophrenia, Global Licensing Deals by Region, Value and Year 2006–2018 46

Figure 20: Schizophrenia, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018 47

Figure 21: Schizophrenia, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target Class, 2006–2018 48

Figure 22: Schizophrenia, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 49

Figure 23: Schizophrenia, Global, Co-development Deals by Region, Value and Year 2006–2018 50

Figure 24: Schizophrenia, Global, Number and Aggregate Deal Value of Co-development Deals By Stage of Development and Year, 2006–2018 51

Figure 25: Schizophrenia, Global, Number and Aggregate Deal Value of Co-development Deals by Molecular Target Class, 2006–2018 52

Figure 26: Schizophrenia, Global, Co-development Deals with Disclosed Deal Values, 2006–2018 52

Figure 27: Schizophrenia, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 53

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards